[Sinovac Reports Unaudited Third Quarter 2016 Financial Results BEIJING, Nov. 28, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter ended September 30, 2016. Mr. Weidong Yin, Chairman, Presid]
[filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be otherwise subject to t]
[Sinovac Reports Unaudited Third Quarter 2016 Financial Results BEIJING, Nov. 28, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter ended September 30, 2016. Mr. Weidong Yin, Chairman, Presid]
[filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be otherwise subject to t]
[Joint Filing Agreement YY Inc. Duowan Entertainment Corporation] []
[SCHEDULE 13G 2 iKang Healthcare Group, Inc. (Name of Issuer) Class A common shares, par value US$0.01 per share, including in the form of American Depositary Shares (each representing 1/2 of a Class A common share) (Title of Class of Securities) 45174L108 (CUSIP Number) December 31, 2016 (Date of Ev]
[Joint Filing Agreement YY Inc. Duowan Entertainment Corporation] []
[SCHEDULE 13G 2 iKang Healthcare Group, Inc. (Name of Issuer) Class A common shares, par value US$0.01 per share, including in the form of American Depositary Shares (each representing 1/2 of a Class A common share) (Title of Class of Securities) 45174L108 (CUSIP Number) December 31, 2016 (Date of Ev]
